Dermagran BC

Quick links to important sections

Dermagran BC

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dermagran BC

Property Description
Active ingredient Zinc Oxide
Form Cream, Ointment, Paste, Hydrophilic Dressing
Pharmacological class Topical Protectant
Common use Protection against minor skin irritations
Origin Inorganic (Mineral-derived)

The Identity and Classification of Dermagran BC

Dermagran BC is a specific topical pharmaceutical preparation whose identity is fundamentally defined by its single active ingredient, Zinc Oxide. It is classified as a topical protectant, belonging to the functional pharmacological group of dermatological protectants and miscellaneous topical agents. This medicine is designed strictly for external use only and is generally marketed as an Over-the-Counter (OTC) medicine.

The product's classification is based on the therapeutic function of Zinc Oxide Topical. Its composition is unique as an inorganic, mineral-derived compound, ensuring its therapeutic action is purely physical and non-systemic, as absorption into the bloodstream is considered negligible. This physical mechanism is the core feature differentiating it from systemically active medications.

Forms, Vehicle, and General Therapeutic Purpose

Dermagran BC is supplied in several dosage forms optimized for topical application, frequently including a traditional, viscous paste, a lighter cream or ointment, or specifically incorporated into a specialized hydrophilic wound dressing. The active ingredient is suspended within an emollient base that typically includes components such as petrolatum and mineral oil.

The general therapeutic purpose of Dermagran BC is to maintain the integrity of the skin. By establishing a continuous physical barrier formation on the skin's surface, the medicine acts to shield the underlying sensitive tissue from external stressors, friction, and excess moisture. This protective function is recognized for mitigating the factors that exacerbate minor skin conditions and supporting a stable environment for natural skin recovery.

Regulatory References

  1. DailyMed

What side effects are possible with Dermagran BC?

Possible Side Effects and Safety Information

Dermagran BC, which contains the topical protectant Zinc Oxide, has a safety profile characterized by minimal systemic risk, as its absorption into the bloodstream is considered negligible. Consequently, the officially documented adverse reactions are almost exclusively localized to the site of application.


Official Adverse Reaction Profile

Adverse reactions associated with this medicine are generally classified under Skin and Subcutaneous Tissue Disorders. They primarily involve localized effects, which may include skin irritation, rash, or itching at the area where the product is applied. Due to the generally low incidence of these effects, their frequency is often classified in regulatory documents as Incidence Not Known.

Serious adverse reactions are rare but may include signs of a severe allergic reaction (such as trouble breathing or swelling of the face/throat), which is a general risk for any topical medication and requires immediate cessation of use.


Safety Considerations and Restrictions

The medicine is contraindicated for use in individuals with known hypersensitivity to any of its components, including excipients in the formulation. Official safety labels contain specific warnings regarding the product base, noting the potential for certain excipients (like wool fat or cetostearyl alcohol) to cause localized skin reactions. Users must avoid contact with the eyes.

For population-specific safety, official information notes that due to minimal systemic absorption, the risk during pregnancy and lactation is considered low. However, specific adverse effect data for older adults or pediatric populations (under 6 months) is often limited in regulatory texts.

A non-pharmacological safety note included in official labeling concerns flammability: fabric (such as clothing or bedding) that has been saturated or coated with this product may burn more easily, constituting a fire hazard.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Dermagran BC (Zinc Oxide topical) consistently defines the potential overdose risk based on accidental ingestion of the product, rather than excessive external application. Zinc Oxide is a topical protectant with negligible absorption into the systemic circulation, meaning systemic toxicity from the intended use is considered extremely unlikely.


Official Overdose Manifestations and Actions

Overdose Context
Documented Manifestations Symptoms following accidental ingestion primarily involve the gastrointestinal tract, including nausea, vomiting, and stomach upset.
Severity Classification Acute toxicity from the ingested topical preparation is officially classified as not very poisonous.

Required Emergency Response

The primary concern requiring immediate action is the unintended oral route of exposure (swallowing the product).

  • When to Seek Urgent Help: Regulatory labeling explicitly mandates that users seek immediate medical attention or call a Poison Control Center right away if the medicine is swallowed.
  • Supportive Management: The official guidance for accidental ingestion confirms that treatment is symptomatic and supportive, as no specific antidote is known for Zinc Oxide toxicity. Monitoring tests, such as blood and urine tests, may be performed by medical professionals.

Therapeutic Uses of Dermagran BC

The use of Dermagran BC is primarily focused on areas where symptoms relate to inflammatory or irritative states. Its therapeutic value lies in providing symptomatic relief and protective coverage to maintain a sense of stability when symptoms are more noticeable.

Managing Symptoms of Moisture- and Friction-Related Rashes

Dermagran BC is generally used for managing symptoms associated with common conditions like diaper dermatitis and chafing. The product is commonly used to help with symptoms that interfere with daily functioning. This may assist with symptoms of localized redness, inflammation, and superficial soreness, which can create noticeable interference with daily stability. The preparation is relevant in contexts marked by increased discomfort or tension, providing support that helps ease the overall symptom burden.

Supportive Relief for Minor Skin Injuries and Environmental Damage

The product is relevant in contexts involving heightened systemic burden for minor cuts, scrapes, and abrasions. It may also be applied in addressing symptom clusters related to environmental damage, such as windburn or chapped skin. This supportive use is appropriate in scenarios where short-term symptomatic assistance is needed, and contributes to improved comfort during symptomatic periods.

Quick Fact: Support for Superficial Discomfort Symptoms
Helps address symptom clusters related to inflammatory or irritative states, such as redness, soreness, and tenderness.

Regulatory References

  1. NIH DailyMed overview for Zinc Oxide

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dermagran BC — official regulatory information


Eligibility scope

Classification Status According to Regulatory Documents
Populations Allowed Adults and Children are permitted for use as an Over-the-Counter (OTC) skin protectant, specifically for conditions like diaper rash.
Populations Contraindicated Patients with known hypersensitivity or allergy to Zinc Oxide or any ingredient in the specific formulation.
Use Not Recommended Use is not recommended for application on large sores, deep puncture wounds, animal bites, or serious burns.

Age-related eligibility rules:

Age Group Eligibility Status
Infants (<4 Weeks) Safety and efficacy are not established for very young infants or very-low-birth-weight infants.
Older Adults (Geriatric) No information is available (or appropriate studies have not been performed) to establish age-specific effects.

Special Population Status:

  • Pregnancy: The manufacturer makes no specific recommendation regarding use. Some labeling advises consulting a health professional.
  • Lactation (Breastfeeding): Data on excretion into human milk is unavailable, and no recommendation is made by the manufacturer.
  • Organ Function (Renal/Hepatic): No specific restrictions or dose adjustments are documented in regulatory labeling due to the non-systemic nature of the product.

Connection to the overall eligibility profile:

Official regulatory documents define eligibility primarily by two factors: the local condition of the application site and individual sensitivity. The medicine is contraindicated for those with known allergies and must not be used on severe or large surface injuries. For all other populations, including pregnant and breastfeeding individuals, eligibility is generally permitted as an OTC topical, but specific data are noted as not established or unavailable for certain vulnerable age groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Dermagran BC, which contains Zinc Oxide as its sole active ingredient, is strictly governed by its classification as a non-systemic, topical protectant. Regulatory documentation confirms that interactions are limited to the application site and do not involve systemic pharmacokinetic or pharmacodynamic effects.

Systemic Drug Interactions

Official government sources do not document interactions between Dermagran BC and systemically administered medicines (e.g., orally or intravenously taken medications). This is because the active ingredient, Zinc Oxide, is not absorbed into the bloodstream in clinically significant amounts, eliminating the basis for metabolic (CYP-mediated), transporter-based, or systemic pharmacodynamic interactions.

Topical Administration Interference

The most relevant constraint documented in labeling is the potential for Topical-Topical Administration Interference. As a physical barrier, Dermagran BC may impede the local action or absorption of other topical medicinal products if they are applied simultaneously to the same area of skin.

Therefore, a regulatory constraint exists regarding the timing of administration of Dermagran BC relative to other preparations. Co-application is restricted to ensure the efficacy of the other topical medicine, requiring separation rather than a formal contraindication.

No interactions with food, alcohol, dietary supplements, or herbal products are specified in official regulatory documents.

Mechanism of Action

Local pH and Moisture Modulation

Dermagran BC functions as an active matrix designed to establish and maintain a slightly acidic pH range (typically 4.0 - 5.5) and optimal moisture balance within the localized tissue environment. This controlled physicochemical milieu modulates the activity of endogenous tissue-degrading enzymes, contributing to a necessary shift in the tissue repair cascade by favoring conditions conducive to cellular proliferation over enzymatic degradation.


Nutrient Cofactor Delivery and Pathway Support

The formulation incorporates essential micronutrients, such as Zinc and select Vitamins, which serve mechanistically as exogenous cofactors. These cofactors are delivered directly to the tissue to influence critical enzymatic pathways necessary for processes like collagen synthesis and cellular proliferation by acting as structural components or activators for metalloenzymes, thereby supporting the regulation of the tissue repair cascade.


Facilitation of Autolytic Debridement

The targeted local environment—specifically the regulated moisture and pH—engages mechanisms that initiate and enhance the autolytic debridement cascade. This process supports the controlled lysis and removal of non-viable tissue by the body's own proteases. This action limits the presence of inflammatory mediators and necrotic debris, consequently influencing subsequent cellular repair stages and preparing the wound base for regenerative processes.

Dosage and Administration Information

General Instructions for Use

Dermagran products are classified either as a Wound Dressing (a medical device) or as a topical preparation containing zinc oxide. Usage instructions describe the proper external administration and management of the product for wound care, based on its designated form.

Administration Scope Requirement
Route of Administration External application only; applied to the skin surface or the external wound area.
Product Form The product is a Dressing, Wound, Drug or a topical application (cream, ointment, paste) containing zinc oxide.
Application Procedure The dressing or preparation is applied to the wound site, such as unhealed pressure ulcers, and may be left in place; it may also be covered with a secondary dressing.
Wound Environment The preparation is intended to create and maintain a moist wound environment and is noted to aid in removing devitalized tissue (debridement).
Dosing Schedule The topical preparation is applied as needed to the affected area; dressing change frequency should follow professional guidance for wound care.
Follow-Up Condition If the affected skin area shows no improvement within 7 days, or if it becomes worse, a check with a healthcare professional is required.

The use of Dermagran BC and related products is characterized as an external, topical procedure for wound management. The administration is focused on applying the product to the affected area to maintain wound conditions conducive to healing. Use is constrained by wound type, and a defined time limit (7 days) is set for requiring medical follow-up if the condition does not improve.

Recent Clinical Evidence

Research evidence / Overview of studies for Dermagran BC

Evidence for Use in Diaper Dermatitis and Irritant Rashes

The core research for Dermagran BC, a topical protectant, has explored its function in conditions characterized by inflammatory or irritative states caused by moisture and friction, primarily diaper dermatitis. This area has been a subject of randomized controlled trials (RCTs), which are recognized as a high standard of research, as well as several large-scale systematic reviews that combine findings from multiple trials. Research has explored both the use of the product when symptoms are present and its function in preventing symptoms from occurring.

In these studies, researchers monitored outcomes related to physical discomfort and changes in the affected skin area. Trials reported that when the protectant was studied for existing rashes, the findings describe patterns observed in the rate at which skin irritation evolved. For prevention, research often examined how long it took for a rash to develop compared to the alternative agent examined in the study. The evidence describes how symptoms evolved in the observed populations during periods of heightened symptom activity.


Study Designs, Measured Outcomes, and Populations

The primary study designs used in research exploring short-term symptom changes involved short-term RCTs that typically lasted only a few days to one week. The outcomes linked to inflammatory or irritative states that research examined included clinical severity scales (tools doctors use to rate the intensity of a rash) and time-to-event metrics (the duration assessed for rash resolution or time until rash onset). These studies also focused on patient-reported outcomes describing perceived discomfort.

The bulk of the controlled research focused on infants and neonates, evaluating its use for diaper rash. Outside of infants, the evidence for use in other age groups, such as adults with frictional or moisture-related dermatoses, comes primarily from broader reviews. The results apply only to the populations studied, meaning the most structured evidence is for infants.


Research Gaps and Follow-up Limitations

The typical follow-up durations were limited in the primary clinical trials, with most acute treatment studies was observed in defined time intervals of seven consecutive days or less. Due to this structure, there is limited information for long-term outcomes related to the continuous use of the product. Furthermore, comparative evidence is lacking for a direct, universally applicable description against all similar products because studies often compared the protectant to a variety of different compounds. The existing data for certain groups remain insufficient, and the evidence structure remains limited when considering situations or populations not explicitly included in the core clinical research.

Key Studies & References Label: ZINC OXIDE 20%- zinc oxide ointment - DailyMed (NIH)

Frequently Asked Questions (FAQ)

Common questions about Dermagran BC (FAQ)

Q: How quickly should I see results from using Dermagran BC?

Regulatory documents do not establish a precise timeline for when users should expect to see results from this topical protectant. However, official guidance advises that if the affected skin area shows no improvement or worsens within 7 days of use, a healthcare professional should be consulted for a re-evaluation.


Q: Is it normal to feel a slight burning sensation when applying Dermagran BC?

The official adverse reaction profile lists common localized effects such as skin irritation, rash, and itching. A burning sensation has been reported in association with these localized effects. If severe burning, stinging, or any sign of a severe allergic reaction occurs, such severe reactions generally require the product to be discontinued and professional medical advice to be sought.


Q: Can Dermagran BC be used on children or babies?

Official documentation includes permission for use in children and indicates its use for conditions like diaper rash in infants. However, regulatory safety data notes that safety and effectiveness are not established for the very youngest infants (those under four weeks old) or for very-low-birth-weight infants.


Q: Is Dermagran BC safe for use during pregnancy or breastfeeding?

Due to its non-systemic nature (meaning it is not absorbed into the bloodstream in significant amounts), the risk is generally considered low. However, the manufacturer makes no specific recommendation, and data on excretion into human milk are unavailable; consultation with a health professional is generally recommended in these situations.


Q: How does the Vitamin B in Dermagran BC help wound healing?

The Dermagran BC formulation includes essential micronutrients, such as Zinc and select Vitamins. These micronutrients are generally considered cofactors that support metabolic processes within the tissue that are necessary for repair, according to the product documentation.


Q: Why does my wound still look red after using Dermagran BC for a few days?

Redness can be related to the wound healing process or may be a sign of irritation. If the skin area shows no improvement or appears to be worsening after 7 days, official guidance requires that a medical professional be consulted.


Q: Why is Dermagran BC sometimes prescribed for diabetic ulcers?

Official regulatory notifications indicate that Dermagran-B type products are intended for wound management on chronic wounds. These indications cover conditions such as diabetic ulcers, pressure ulcers (up to Stage 4), and venous stasis ulcers.


Q: Is Dermagran BC available over the counter?

The active ingredient, Zinc Oxide, is classified as an Over-the-Counter (OTC) topical protectant. Its regulatory classification means that the product is typically marketed as an Over-the-Counter (OTC) product.


Q: What should I do if I forget to apply a dose of Dermagran BC?

Since this topical preparation is generally applied 'as needed' rather than on a strict schedule, there is no formal missed dose protocol. If a topical application is missed, the guidance is generally to apply it when remembered, taking care not to apply excessive amounts.


Q: Can Dermagran BC be used on open cuts or lacerations?

Official product indications include use on superficial lacerations, cuts, or abrasions. However, regulatory safety restrictions note that the product is not recommended for use on large sores, deep puncture wounds, or animal bites.


Q: Does Dermagran BC expire?

Yes, as a regulated drug product, the container is required to have an expiration date printed by the manufacturer. Using the product past this date may affect its quality and effectiveness, as its stability and potency are no longer guaranteed.


Q: What is the difference between Dermagran BC and a simple zinc oxide cream?

The Dermagran BC preparation is regulated as a specialized wound dressing that includes the active ingredient Zinc Oxide. It is often formulated with a zinc-nutrient base and a mildly acidic pH intended to create an environment that supports tissue repair, which simple zinc oxide creams may lack.


Q: Can Dermagran BC be used on the face?

Regulatory labeling warns against contact with the eyes. While application to the facial skin is not explicitly restricted, caution should be taken to avoid sensitive areas, and the product is intended for external, localized use on affected areas.


Q: Is it okay if Dermagran BC gets into the wound itself?

Yes. The product is intended for wound management, where the preparation or dressing is applied directly to the wound site, such as an ulcer or incision, to maintain conditions that promote healing, according to the instructions for use.


Q: What happens if I use too much Dermagran BC?

As a non-systemic topical product, systemic toxicity from external overuse is considered negligible. Using an excessive amount may increase the potential for localized skin reactions. In the event of accidental ingestion, instructions specify that a Poison Control Center should be contacted.


Q: Can people with sensitive skin use Dermagran BC?

Official information states that the product is contraindicated only for those with a known allergy or hypersensitivity to its components. However, safety labels warn that some inactive ingredients in the product base (such as certain alcohols) are known to occasionally cause localized skin reactions in sensitive individuals.


Q: How soon after application can I cover the area with clothing or a bandage?

The primary safety warning related to covering the area concerns flammability. This warning highlights a fire hazard risk when fabric or bedding is saturated or heavily coated with the product, as it may burn more easily.


Q: Can Dermagran BC be used on burns?

Official product indications include use on minor, superficial, partial-thickness thermal burns. However, regulatory restrictions state that the product is explicitly not recommended for the treatment of serious burns (third-degree burns).

How should Dermagran BC be stored and disposed of?

How to Store and Dispose of Dermagran BC?

This section outlines the official requirements for storing and discarding the product, based on government regulatory documentation.

Storage and Handling

Requirement Official Instruction
Temperature Store at Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F).
Protection Keep the container cap tightly closed when not in use to protect the product.
Child Safety Keep this and all medicines out of the reach of children. If swallowed, contact a Poison Control Center immediately.

Disposal Rules

Disposal must be conducted according to applicable government regulations. For non-hazardous, non-flushable medicines, general guidance advises mixing the product with an unpalatable substance, such as coffee grounds, sealing the mixture in a container or bag, and placing it in the household trash. Empty packaging should have all personal information scratched out before disposal. Avoid flushing medicines down the sink or toilet to prevent environmental harm unless specifically instructed by a regulator.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dermagran BC found in:

A-Z Index: